The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Kazia Therapeutics Limited is seeking various regulatory designations from the FDA to support its drug development pipeline.
- Kura Oncology is seeking an Investigational New Drug (IND) application for its drug candidate KO-7246.
- The FDA recommended advancement for a new drug application submitted by a company.
- FDA granted Orphan Drug Designation to BAL0891, a therapeutic targeting the TTK protein, developed by Hanmi Pharmaceutical.
- The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.
Coverage
Newest first; wire copies grouped- GlobeNewswireKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Ker